Opinion
Video
Managing EDS in Patients With OSA and Accessing Therapy Effectiveness
Author(s):
Panelists discuss how FDA-approved medications like modafinil, armodafinil, and solriamfetol serve both therapeutic and diagnostic purposes in treating residual sleepiness, with responses varying across different sleep disorder populations but consistently helping patients recognize their true level of impairment.
Video content above is prompted by the following:
Current pharmacological options for obstructive sleep apnea (OSA)–related excessive daytime sleepiness include modafinil, armodafinil, and solriamfetol, all FDA-approved for treating residual sleepiness in optimally treated patients with sleep apnea. These medications work through dopaminergic and noradrenergic pathways, offering rapid onset of action and generally favorable tolerability profiles. The quick therapeutic response allows for diagnostic utility—patients often gain new insight into their baseline sleepiness level when experiencing normal alertness for the first time in years.
Clinical experience suggests variable medication responses across different sleep disorders. Shift work sleep disorder patients often show robust responses, possibly reflecting their severe circadian disruption and high baseline sleepiness levels. Narcolepsy patients typically respond well, though individual variation exists. OSA patients represent the most heterogeneous group, with responses varying based on factors including OSA severity, CPAP compliance, and individual physiological differences in sleep-wake regulation systems.
Future therapeutic developments focus on targeting multiple neurotransmitter systems involved in wakefulness promotion. Current medications primarily affect dopamine and norepinephrine reuptake, but the complexity of sleep-wake regulation suggests potential for novel approaches targeting histamine, orexin, and other arousal systems. The clinical goal remains optimizing individual patient outcomes through personalized treatment approaches that may combine mechanical therapy, pharmacological intervention, and lifestyle modifications to achieve maximal functional improvement and quality of life restoration.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
